IOVANCE BIOTHERAPEUTICS INC (IOVA)
US4622601007 - Common Stock
Taking everything into account, IOVA scores 3 out of 10 in our fundamental rating. IOVA was compared to 564 industry peers in the Biotechnology industry. The financial health of IOVA is average, but there are quite some concerns on its profitability. While showing a medium growth rate, IOVA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
IOVA had negative earnings in the past year.
IOVA had a negative operating cash flow in the past year.
IOVA had negative earnings in each of the past 5 years.
IOVA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
IOVA has a Return On Assets (-41.37%) which is in line with its industry peers.
With a decent Return On Equity value of -53.01%, IOVA is doing good in the industry, outperforming 64.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.37% | ||
| ROE | -53.01% | ||
| ROIC | N/A |
ROA(3y)-53.52%
ROA(5y)-50.33%
ROE(3y)-70.08%
ROE(5y)-63.17%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IOVA's Gross Margin of 14.75% is fine compared to the rest of the industry. IOVA outperforms 74.15% of its industry peers.
IOVA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 14.75% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IOVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IOVA has been increased compared to 1 year ago.
Compared to 5 years ago, IOVA has more shares outstanding
Compared to 1 year ago, IOVA has an improved debt to assets ratio.
2.2 Solvency
IOVA has an Altman-Z score of 2.29. This is not the best score and indicates that IOVA is in the grey zone with still only limited risk for bankruptcy at the moment.
IOVA's Altman-Z score of 2.29 is fine compared to the rest of the industry. IOVA outperforms 71.81% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that IOVA is not too dependend on debt financing.
The Debt to Equity ratio of IOVA (0.00) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.29 |
ROIC/WACCN/A
WACC10.61%
2.3 Liquidity
IOVA has a Current Ratio of 4.22. This indicates that IOVA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.22, IOVA perfoms like the industry average, outperforming 48.29% of the companies in the same industry.
IOVA has a Quick Ratio of 3.90. This indicates that IOVA is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.90, IOVA perfoms like the industry average, outperforming 47.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.22 | ||
| Quick Ratio | 3.9 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 28.02% over the past year.
Looking at the last year, IOVA shows a very strong growth in Revenue. The Revenue has grown by 12696.90%.
EPS 1Y (TTM)28.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.13%
Revenue 1Y (TTM)12696.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12385.07%
3.2 Future
Based on estimates for the next years, IOVA will show a very strong growth in Earnings Per Share. The EPS will grow by 20.33% on average per year.
The Revenue is expected to grow by 214.29% on average over the next years. This is a very strong growth
EPS Next Y31.48%
EPS Next 2Y25.42%
EPS Next 3Y23.18%
EPS Next 5Y20.33%
Revenue Next Year3733.88%
Revenue Next 2Y920.51%
Revenue Next 3Y448.76%
Revenue Next 5Y214.29%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IOVA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IOVA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IOVA's earnings are expected to grow with 23.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.42%
EPS Next 3Y23.18%
5. Dividend
5.1 Amount
IOVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IOVANCE BIOTHERAPEUTICS INC
NASDAQ:IOVA (1/3/2025, 8:00:02 PM)
After market: 7.65 0 (0%)7.65
-0.14 (-1.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners78.82%
Inst Owner Change1.19%
Ins Owners0.19%
Ins Owner Change8.79%
Market Cap2.33B
Analysts81.9
Price Target24.24 (216.86%)
Short Float %21.47%
Short Ratio8.46
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.96%
Min EPS beat(2)5.66%
Max EPS beat(2)8.26%
EPS beat(4)3
Avg EPS beat(4)3.56%
Min EPS beat(4)-2.23%
Max EPS beat(4)8.26%
EPS beat(8)7
Avg EPS beat(8)11.6%
EPS beat(12)9
Avg EPS beat(12)7.84%
EPS beat(16)9
Avg EPS beat(16)5.23%
Revenue beat(2)2
Avg Revenue beat(2)15.36%
Min Revenue beat(2)6.69%
Max Revenue beat(2)24.03%
Revenue beat(4)2
Avg Revenue beat(4)-25.39%
Min Revenue beat(4)-66.23%
Max Revenue beat(4)24.03%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.44%
EPS NY rev (1m)0%
EPS NY rev (3m)1.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.17%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 25.66 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.01 | ||
| P/tB | 4.99 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.49
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0.3
BVpS2.54
TBVpS1.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.37% | ||
| ROE | -53.01% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 14.75% | ||
| FCFM | N/A |
ROA(3y)-53.52%
ROA(5y)-50.33%
ROE(3y)-70.08%
ROE(5y)-63.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 33.11% | ||
| Cap/Sales | 11.48% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.22 | ||
| Quick Ratio | 3.9 | ||
| Altman-Z | 2.29 |
F-Score6
WACC10.61%
ROIC/WACCN/A
Cap/Depr(3y)510.52%
Cap/Depr(5y)1245.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.13%
EPS Next Y31.48%
EPS Next 2Y25.42%
EPS Next 3Y23.18%
EPS Next 5Y20.33%
Revenue 1Y (TTM)12696.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12385.07%
Revenue Next Year3733.88%
Revenue Next 2Y920.51%
Revenue Next 3Y448.76%
Revenue Next 5Y214.29%
EBIT growth 1Y3.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.11%
EBIT Next 3Y19.81%
EBIT Next 5Y13.55%
FCF growth 1Y-27.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.22%
OCF growth 3YN/A
OCF growth 5YN/A